-
Cell Research: New Advances in Chronic Pain Treatment
Time of Update: 2022-04-22
Yang Huaiyu from the School of Life Sciences of East China Normal University published an online publication in the journal Cell Research entitled Inhibiting Hv1 channel in peripheral sensory neurons attenuates chronic inflammatory pain and A research paper on opioid side effects, for the first time reporting that the voltage-gated proton channel (Hv1) is a new target for the treatment of chronic pain .
-
Strong pharmaceutical demand drives the development of pharmaceutical machines, and many companies such as Canaan Technology have achieved gratifying performance
Time of Update: 2022-04-15
Regarding the changes in performance, Canaan Technology said that during the reporting period, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses in the entire industry chain to ensure the company's oral solid preparation equipment, biological preparation fluid equipment and various businesses.
-
"Have a tumor, but died of a heart attack
Time of Update: 2022-03-02
In May 2021, Zhongshan Hospital opened a special outpatient clinic for oncology and cardiology, which opened a new window for cancer patients with cardiovascular disease .
-
"Nature": ctDNA testing helps personalized diagnosis and treatment of bladder cancer
Time of Update: 2021-07-31
CtDNA from solid tumors is released into the bloodCtDNA from solid tumors is released into the bloodAccording to a clinical study conducted by Queen Mary University of London, blood tests related to ctDNA may be able to identify the risk of cancer recurrence and guide the precise treatment of bladder cancer after surgery.
-
Another domestic third-generation EGFR inhibitor applied for listing and CSPC obtained exclusive authorization
Time of Update: 2021-07-01
On May 7, the official website of the National Medical Products Administration (NMPA) showed that Shanghai Beierda Pharmaceuticals submitted a listing application for the first class of new drug Rezetinib Mesylate Capsules (BPI-7711), which is an irreversible and high choice The third-generation small molecule epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKI ) has significant inhibitory activity against EGFR sensitive mutations and EGFR T790M resistant mutations .
-
Innovative drug development choices: stand alone or flourish
Time of Update: 2021-04-18
The number of IPO listed companies has increased across the board, and the Science and Technology Innovation Board, Hong Kong Stocks, Main Board, and even U.
; Talent flow and technological blessing have also accelerated the increase in the number of innovative pharmaceutical companies in China, attracting attention.
-
Scientists develop new drug to fight gut 'superbugs
Time of Update: 2020-12-21
Australia's Flinders University has announced that researchers have developed a new antibiotic that animal experiments have shown can be effective in suppressing a drug-resistant gut "superbug." bacteria "resist" antibiotics in many forms to escape the risk of extinction, a resistance known as "bacterial resistance." Superbugs are bacteria that are resistant to a variety of antibiotics, and patients lack effective treatment after contracting superbugs.
-
Yuandong Bio "Grom bromine ammonium injection" is about to be approved for the second time
Time of Update: 2020-10-21
Compared with Athosin, ammonium Glon bromide inhibits salivary secretion for a strong and long-lasting effect, with low cardiovascular adverse reactions, and the drug lipid membrane has poor passability and is not easy to pass through the blood-brain barrier, thus affecting the central nervous system less.
-
Progress in the study of immunocheckpoint inhibitors targeting tumor
Time of Update: 2019-08-06
In recent years, tumor immunotherapy has developed rapidly, and many tumor patients have benefited from it But clinical data show that immunotherapy is very inefficient for a considerable number of tu
-
Weekly trend of consistency evaluation: over evaluated enterprises gradually over compete
Time of Update: 2019-07-12
As of July 11th, a total of 1263 acceptance numbers (373 varieties of 377 enterprises, according to the supplementary application, the same below) have been accepted by CDE, of which 222 (96 varieties
-
Nat commun: new research reveals the cause of brain damage in stroke! A new stroke drug is on the way
Time of Update: 2018-03-16
March 16, 2018 / bioin / - new research reveals how a new drug qnz-46 can help alleviate the effects of brain over release of glutamate (the main cause of brain damage caused by stroke) Photo source:
-
Chem. Commun.: Suzuki miyaara reaction is applied to the synthesis of drugs rich in SP3 hybrid atoms
Time of Update: 2017-12-27
An increasingly important consideration in modern pharmaceutical chemistry is the overall control of the physical and chemical properties of candidate drugs With regard to this high-level objective, t
